[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gallstone-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gallstone-disease":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,50,77,100,126,154],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100627788","transabdominal-and-laparoscopic-ultrasound-in-a-bariatric-setting-100627788",false,"NCT07453186","Transabdominal and Laparoscopic Ultrasound in a Bariatric Setting","Transabdominal and Laparoscopic Ultrasound in a Bariatric Setting: Utility and Diagnostic Accuracy","Inclusion Criteria:\n\n* Age ≥18 years\n* Scheduled for bariatric surgery\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* Previous cholecystectomy\n* Previous biliary surgery\n* Previous liver surgery\n* Inability to provide informed consent",true,"ALL","18 Years",{"count":20,"type":21},130,"ESTIMATED","INTERVENTIONAL",[24],"NA","Every year, many patients undergo weight-loss (bariatric) surgery. While this surgery leads to significant and intended weight loss, it also increases the risk of developing gallstones or other gallbladder problems.\n\nApproximately one in five patients later requires a second operation to remove the gallbladder. This type of surgery carries a higher risk of complications and reoperations compared with gallbladder surgery performed in the general population.\n\nPreventive treatment may help reduce this risk. One option is medical treatment with Ursochol, which has been shown to lower the risk of developing gallstones after bariatric surgery. However, this treatment is only effective in patients who have not already developed gallstones before surgery.\n\nThis means patients need a reliable preoperative ultrasound examination of the gallbladder. Unfortunately, performing ultrasound can be technically challenging in patients with obesity, making it harder to detect small stones or other abnormalities.\n\nThe goal is therefore to improve the examination of the gallbladder in patients undergoing bariatric surgery in order to better identify who may benefit from preventive treatment.\n\nThe study\n\nThe investigators are comparing two types of ultrasound examination of the gallbladder:\n\n* Standard ultrasound performed on the outside of the abdomen using a handheld probe.\n* Laparoscopic ultrasound performed during bariatric surgery using a small ultrasound probe placed inside the abdomen, typically placed on the liver near the gallbladder.\n\nIt is of interest to find out whether the ultrasound performed during surgery finds more:\n\n* Gallstones\n* Sludge\n* Small stones (microlithiasis)\n* Thickening of the gallbladder wall\n\nBy improving detection, the investigators aim to better guide preventive treatment and reduce the need for future gallbladder surgery.",[27,28,29],"Gallstone Disease","Ultrasonic Diagnosis","Bariatric Patients Undergoing Bariatric Surgery",[31,32,33,34,35,36],"Bariatric surgery","Gallstone disease","Metabolic surgery","Biliary disease","Ultrasound","Laparoscopic ultrasound","RECRUITING","2026-05-29",{"date":40,"type":41},"2026-06-02","ACTUAL",{"date":43,"type":41},"2026-04-01",{"date":45,"type":21},"2029-03-01",{"name":47,"class":48},"Esbjerg Hospital - University Hospital of Southern Denmark","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":62,"conditions":63,"keywords":65,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":49},"100492216","gut-microbiome-and-metabolome-in-patients-with-gallstone-disease-after-surgical-and-endoscopic-interventions-100492216","NCT05689255","Gut Microbiome and Metabolome in Patients With Gallstone Disease After Surgical and Endoscopic Interventions","A Prospective Cohort Study of Translational Changes in Gut Microbiome and Metabolome in Patients With Gallstone Disease After Surgical and Endoscopic Interventions","Inclusion Criteria:\n\n* Aged 21 years to 80 years\n* Diagnosis of symptomatic gallstone disease without or with concomitant bile duct stones based on prior diagnostic radiological imaging such as transabdominal ultrasound (US), computed tomography (CT), magnetic resonance imaging (MRI) or endoscopic ultrasound (EUS).\n* Will be scheduled for cholecystectomy with or without concomitant ERCP-ES for treatment.\n* Patient is willing to provide informed consent before enrolment in the study.\n\nExclusion Criteria:\n\n* Subjects undergoing ERCP-ES with no intention for future cholecystectomy\n* Use of antibiotics or probiotics within 1 month (exception: use of antibiotics within 48 hours of cholecystectomy or ERCP, as metagenomics will be able to sequence both dead and live bacteria, and marked compositional change is not expected within this time frame)\n* Presence of malignancy diagnosed within the last 1 year\n* Previous gastrectomy, appendicectomy, small bowel or large bowel surgery\n* Inflammatory bowel disease\n* Active gastrointestinal tract infections","21 Years","80 Years",{"count":60,"type":21},65,"OBSERVATIONAL","The goal of this longitudinal observational cohort study is to examine the changes in the composition and diversity of gut microbiome and systemic metabolome in patients with symptomatic gallbladder stones with or without concomitant common bile duct (CBD) stones who will be undergoing cholecystectomy with or without prior endoscopic sphincterotomy (ERCP-ES) and CBD stones extraction. The main questions it aims to answer are whether there are:\n\n* differences in gut microbiome diversity and composition before and after cholecystectomy\n* differences in systemic metabolome before and after cholecystectomy\n* gut microbiome and systemic metabolome changes after cholecystectomy\n\nParticipants will be asked to provide stool, urine, plasma and saliva samples prior to and 1-6 months after cholecystectomy. For patients with concomitant CBD stones who undergo ERCP-ES before cholecystectomy, bile specimens will be collected from the bile duct during ERCP-ES as well as the gallbladder and\u002For during cholecystectomy.",[27,64],"Bile Duct Diseases",[66,67],"microbiome","metabolome","2026-04-06",{"date":70,"type":41},"2026-04-09",{"date":72,"type":41},"2022-12-23",{"date":74,"type":21},"2026-12-31",{"name":76,"class":48},"Changi General Hospital",{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":87,"conditions":88,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":99},"100530894","eulat-eradicate-gbc-100530894","NCT06192719","EULAT Eradicate GBC","Establishment and Exploitation of a European-Latin American Research Consortium Towards Eradication of Preventable Gallbladder Cancer - EULAT Eradicate GBC","EULAT","Inclusion Criteria:\n\n1. Cohort A. Patients with gallbladder cancer or dysplasia, both before and after the start of their anticancer treatment.\n\n   Cohort B. Patients with cholelithiasis before cholecystectomy (only patients scheduled for cholecystectomy will be recruited)\n2. Diagnosis confirmed in accordance with standard protocols of the participating hospitals\n3. Men and women aged 18 or over\n\nExclusion Criteria:\n\n1. Any medical condition that present an unreasonable risk to the participant.\n2. Any psychiatric condition that interferes with understanding informed consent.",{"count":86,"type":21},15000,"Gallstones are relatively frequent in women and constitute one of the main risk factors for gallbladder cancer (GBC).\n\nCurrently, GBC diagnosis is mainly based on imaging (ultrasound or abdominal CT) associated with invasive examinations (biopsy and surgery), with no marker available to date to accurately predict risk and diagnose the disease early. The only curative treatment for GBC remains surgery with complete resection of tumors in early stages.\n\nGiven the aggressiveness of GBC and the very limited therapeutic options, as well as the possibility of preventing GBC by cholecystectomy during the 10 to 20 years required for the development of gallbladder tumors, it is imperative to develop effective and efficient prevention strategies based on a prioritization of interventions according to environmental and genetic-molecular risk factors.\n\nThe investigators aim to identify epidemiological factors linked to the development of GBC, and to identify, validate and functionally characterize genetic-molecular markers in blood, saliva, urine, bile and stool that allow risk prediction, early diagnosis and precision treatment of incidental tumors.",[89,27],"Gallbladder Cancer","2026-02-16",{"date":92,"type":41},"2026-02-18",{"date":94,"type":41},"2019-12-01",{"date":96,"type":21},"2028-12-31",{"name":98,"class":48},"Centre Paul Strauss",36,{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":4,"eligibilityCriteria":106,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":107,"enrollmentInfo":108,"targetDuration":4,"studyType":22,"phases":109,"briefSummary":111,"conditions":112,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":123,"locationsCount":49},"100625313","phase-1-pharmacokinetics-bioequivalence-and-safety-study-of-trimedat-7695-mg-orally-disintegrating-tablets-and-trimedat-100-mg-tablets-in-healthy-volunteers-100625313","NCT07421011","Pharmacokinetics, Bioequivalence, and Safety Study of Trimedat® 76,95 mg Orally Disintegrating Tablets and Trimedat® 100 mg Tablets in Healthy Volunteers.","A Randomized, Open-label, Crossover Study to Assess the Comparative Pharmacokinetics, Bioequivalence, and Safety of Trimedat® 76,95 mg Orally Disintegrating Tablets and Trimedat® 100 mg Tablets in Healthy Volunteers.","Inclusion Criteria:\n\n1. Voluntarily and personally signed informed consent form by a healthy volunteer obtained prior to the conduct of any study-related procedure;\n2. Males and females aged 18 to 45 years (inclusive) of Caucasian race.;\n3. Verified healthy status as demonstrated by the absence of clinically significant abnormalities in medical history, physical and instrumental examination, laboratory tests, and other diagnostic procedures specified in the protocol;\n4. Blood pressure (BP) level: systolic blood pressure (SBP) from 100 to 130 mm Hg (inclusive), diastolic blood pressure (DBP) from 70 to 89 mm Hg (inclusive);\n5. Heart rate (HR) from 60 to 89 beats per minute (inclusive);\n6. Respiratory rate (RR) from 12 to 20 breaths per minute (inclusive);\n7. Body temperature from 36.0°C to 36.9°C (inclusive);\n8. Body mass index (BMI) between 18.5 kg\u002Fm² and 30 kg\u002Fm², with a minimum body weight of ≥ 55 kg for men and ≥ 45 kg for women;\n9. Consent to use adequate contraceptive methods throughout the study and for 30 days after its completion, with a negative urine pregnancy test result for women of childbearing potential.\n\nNon-Inclusion Criteria:\n\n1. Clinically significant allergic history;\n2. Hypersensitivity to active and\u002For excipient substances in the investigational drug and comparator drug in the medical history;\n3. Drug intolerance to active and\u002For excipient substances in the investigational drug and comparator drug in the medical history;\n4. Known galactose intolerance, lactase deficiency, or glucose-galactose malabsorption;\n5. Chronic diseases of the kidneys, liver, gastrointestinal tract (GIT), cardiovascular, lymphatic, respiratory, nervous, endocrine, musculoskeletal, urogenital, and immune systems, as well as skin, hematopoietic organs, and the eye;\n6. Surgical interventions on the GIT in the medical history (except for appendectomy performed at least 1 year prior to screening);\n7. Diseases\u002Fconditions that, in the investigator's judgment, may affect the absorption, distribution, metabolism, or excretion of the investigational drugs;\n8. Acute infectious diseases less than 4 weeks before screening;\n9. Use of drugs that significantly affect hemodynamics and drugs affecting liver function (barbiturates, omeprazole, cimetidine, etc.) less than 2 months before screening;\n10. Regular use of medications less than 2 weeks before screening and single use of medications less than 7 days before screening (including over-the-counter drugs, vitamins, dietary supplements, herbal medicines);\n11. Blood or plasma donating within 3 months prior to screening;\n12. Use of hormonal contraceptives (in women) within 2 months prior to screening;\n13. Use of depot injections of any medications within 3 months prior to screening;\n14. Pregnancy or lactation; positive urine pregnancy test result for women of childbearing potential;\n15. Female subjects of childbearing potential who had unprotected sexual intercourse with an unsterilized male partner within 30 days prior to administration investigational drugs;\n16. Participation in another clinical study within 3 months prior to screening or concurrently with this study;\n17. Consumption of more than 10 alcohol units per week (1 unit of alcohol is equivalent to 500 ml of beer, 200 ml of wine, or 50 ml of strong alcoholic beverages) in the last month before inclusion in the study or a history of alcoholism, drug addiction, or substance abuse;\n18. Smoking more than 10 cigarettes per day currently or smoking that amount in the past 6 months prior to screening; unwillingness to refrain from smoking during hospitalization;\n19. Consumption of alcohol, caffeine, and xanthine-containing products within 7 days prior to taking investigational drugs;\n20. Consumption of citrus fruits, cranberries, rose hips and products containing them, or preparations\u002Fproducts containing St. John's wort within 7 days prior to taking investigational drugs;\n21. Dehydration due to diarrhea, vomiting, or other causes within the last 24 hours prior to taking investigational drugs;\n22. Positive blood test for antibodies to human immunodeficiency virus (HIV) types 1 and 2, antibodies to Treponema pallidum antigens, hepatitis B surface antigen (HBsAg), antibodies to hepatitis C virus antigens during screening;\n23. ECG abnormalities in medical history and\u002For during screening;\n24. Positive urine test for narcotic substances and potent medications during screening;\n25. Positive breath alcohol test result during screening;\n26. Planning hospitalization during the study period for any reason other than hospitalization specified in the study protocol;\n27. Inability or unwillingness to comply with protocol requirements, perform procedures prescribed by the protocol, or adhere to dietary and activity restrictions;\n28. Membership in a vulnerable population, including but not limited to students of medical, pharmaceutical and dental educational institutions, junior staff of clinics and laboratories, employees of pharmaceutical companies, military personnel, prisoners, residents of care facillities, individuals with low income or unemployed, members of ethnic minorities, homeless persons, vagrants, refugees, individuals under guardianship or conservatorship, individuals unable to provide informed consent and law enforcement personnel;\n29. Other conditions that in the judgment of the Investigator may prevent volunteer inclusion in the study or lead to premature withdrawal from the study including adherence to fasting or special diets (e.g., vegetarianism, veganism, salt restriction) or special lifestyles (night work, extreme physical exertion).\n\nExclusion Criteria:\n\n1. Withdrawal of the volunteer from further participation in the study;\n2. Non-compliance by the volunteer with the study participation rules (missed study procedures, self-administration of drugs prohibited in the study, violation of dietary and lifestyle restrictions, etc.);\n3. Emergence of reasons\u002Fsituations during the study that threaten the safety of the volunteer (e.g., hypersensitivity reactions, etc.);\n4. Volunteers selected for participation in the study who do not meet inclusion\u002Fexclusion criteria;\n5. Development of a severe and\u002For serios adverse event (AE\u002FSAE) in the volunteer during the study;\n6. The volunteer undergoes or requires treatment that may affect the pharmacokinetic parameters (PKP) of the investigational drugs;\n7. Missed collection of 2 or more consecutive blood samples or 3 or more blood samples within one study period;\n8. Occurrence of vomiting\u002Fdiarrhea within 6 hours after taking the investigational drug;\n9. Positive urine test for narcotic substances and potent medications;\n10. Positive breath test for alcohol vapors;\n11. Positive pregnancy test result in women;\n12. Emergence of other circumstances during the study that preclude conducting the study according to the protocol.","45 Years",{"count":99,"type":21},[110],"PHASE1","This study aims to evaluate pharmacokinetic profile, safety and establish bioequivalence of the investigational drug Trimedat® 76,95 mg orally disintegrating tablets compared to the reference drug Trimedat® 100 mg tablets in healthy volunteers under fasted conditions.",[113,27,114,115,116],"Irritable Bowel Syndrome","GERD","Biliary Dyskinesia","Postcholecystectomy Syndrome","2026-02-11",{"date":119,"type":41},"2026-02-19",{"date":121,"type":41},"2025-11-06",{"date":74,"type":21},{"name":124,"class":125},"Valenta Pharm JSC","INDUSTRY",{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":132,"eligibilityCriteria":133,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":134,"targetDuration":4,"studyType":22,"phases":136,"briefSummary":137,"conditions":138,"keywords":142,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":49},"100616599","tens-for-anxiety-pain-and-satisfaction-after-laparoscopic-cholecystectomy-100616599","NCT07307703","TENS for Anxiety, Pain, and Satisfaction After Laparoscopic Cholecystectomy","Effects of Transcutaneous Electrical Nerve Stimulation (TENS) on Surgical Anxiety, Postoperative Pain, and Patient Satisfaction in Patients Undergoing Laparoscopic Cholecystectomy","TENS-LC","Inclusion Criteria:\n\n* Adults aged 18-65 years scheduled for elective laparoscopic cholecystectomy\n\nASA (American Society of Anesthesiologists) physical status classification I-II\n\nAbility to understand the study procedures and provide written informed consent\n\nNo contraindications to TENS application (e.g., intact skin at electrode placement sites)\n\nWillingness to comply with perioperative assessments (pain, anxiety, satisfaction scales)\n\nExclusion Criteria:\n\n* Patients with ASA III or higher physical status\n\nPresence of cardiac pacemaker or other implanted electrical devices\n\nHistory of epilepsy, severe neuropathy, or psychiatric disorders affecting pain\u002Fanxiety perception\n\nSkin lesions, infections, or dermatological conditions at electrode placement sites\n\nUse of analgesics, anxiolytics, or sedatives beyond standard perioperative protocols\n\nEmergency cholecystectomy or conversion to open surgery\n\nPregnant or breastfeeding women\n\nPatients unwilling or unable to provide informed consent",{"count":135,"type":21},80,[24],"This study is designed to evaluate whether Transcutaneous Electrical Nerve Stimulation (TENS) can improve recovery for patients undergoing laparoscopic gallbladder removal surgery (laparoscopic cholecystectomy). TENS is a non-invasive method that uses mild electrical currents applied through the skin to stimulate nerves.\n\nThe main goals of the study are to determine if TENS can:\n\nReduce surgical anxiety before and during the procedure\n\nDecrease postoperative pain after surgery\n\nImprove overall patient satisfaction with their surgical experience\n\nPatients who participate will receive standard surgical care, and some will also receive TENS therapy. Outcomes will be measured using patient questionnaires and clinical assessments during the hospital stay and follow-up period.\n\nBy comparing patients who receive TENS with those who do not, the study aims to provide evidence on whether this simple technique can enhance comfort and recovery after gallbladder surgery.",[27,139,140,141],"Postoperative Pain","Surgical Anxiety","Patient Satisfaction After Laparoscopic Cholecystectomy",[143,27,140,139,144],"Laparoscopic Cholecystectomy","Transcutaneous Electrical Nerve Stimulation (TENS)","2025-12-15",{"date":147,"type":41},"2025-12-29",{"date":149,"type":41},"2025-12-01",{"date":151,"type":21},"2026-09-30",{"name":153,"class":48},"Nigde Omer Halisdemir University",{"id":155,"slug":156,"hasResults":11,"nctId":157,"briefTitle":158,"officialTitle":159,"acronym":160,"eligibilityCriteria":161,"healthyVolunteers":16,"sex":17,"minAge":107,"maxAge":162,"enrollmentInfo":163,"targetDuration":4,"studyType":22,"phases":165,"briefSummary":166,"conditions":167,"keywords":169,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":49},"100486788","prevention-of-nafld-and-cvd-through-lifestyle-intervention-100486788","NCT05618626","Prevention of NAFLD and CVD Through Lifestyle Intervention","Cardiovascular Diseases (CVD) and Nonalcoholic Fatty Liver Diseases (NAFLD) Among Gallstone and Cholecystectomy Patients and the Impact of a Novel Diet and Muscle Training Program","MAUCO+","Inclusion Criteria:\n\n* With and without gallstones disease\n* With various degrees of NAFLD (none too severe)\n\nExclusion Criteria:\n\n* Any significant comorbidity or physical limitation to undergo resistance exercise program\n* Use of medications that alter muscle mass (e.g., corticosteroids)\n* History of hepatitis B or C\n* Use of hepatotoxic drugs","60 Years",{"count":164,"type":21},300,[24],"Prevention of non-alcoholic fatty liver disease (NAFLD) and cardiovascular disease (CVD) through lifestyle intervention (MAUCO+) is a clinical trial that aims to improve sarcopenia, aerobic capacity, body composition, and lipid profile, insulin resistance, cardiovascular risk, NAFLD, and maintain a healthier lifestyle. Through the implementation of physical activity and nutritional programs.",[168,27],"Non-Alcoholic Fatty Liver Disease",[170,171,172],"Anti-inflammatory diet","Lifestyle modification","Physical Activity","2024-11-17",{"date":175,"type":41},"2024-11-19",{"date":177,"type":41},"2021-09-27",{"date":179,"type":21},"2025-04-30",{"name":181,"class":48},"Pontificia Universidad Catolica de Chile"]